These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26907504)

  • 21. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
    Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
    BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea.
    Shim TS; Pai H; Mok J; Lee SH; Kwon YS; Choi JC; Park J; Birmingham E; Mao G; Alquier L; Davis K; Thoret-Bauchet F; Kim JH; Kim H; Bakare N
    BMC Infect Dis; 2023 Jan; 23(1):15. PubMed ID: 36624432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review.
    Charan J; Reljic T; Kumar A
    Indian J Pharmacol; 2016; 48(2):186-91. PubMed ID: 27127322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
    Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
    Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report.
    Park S; Lee KM; Kim I; Mok J
    Int J Infect Dis; 2018 Nov; 76():88-90. PubMed ID: 30244076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens.
    Park HY; Kwon JW; Kim HL; Kwon SH; Nam JH; Min S; Oh IS; Bea S; Choi SH
    J Korean Med Sci; 2023 May; 38(21):e167. PubMed ID: 37270920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.
    Borisov SE; D'Ambrosio L; Centis R; Tiberi S; Dheda K; Alffenaar JW; Amale R; Belilowski E; Bruchfeld J; Canneto B; Denholm J; Duarte R; Esmail A; Filippov A; Davies Forsman L; Gaga M; Ganatra S; Igorevna GA; Lazaro Mastrapa B; Manfrin V; Manga S; Maryandyshev A; Massard G; González Montaner P; Mullerpattan J; Palmero DJ; Pontarelli A; Papavasileiou A; Pontali E; Romero Leyet R; Spanevello A; Udwadia ZF; Viggiani P; Visca D; Sotgiu G; Migliori GB
    J Infect; 2019 Jan; 78(1):35-39. PubMed ID: 30096332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults.
    Gras J
    Drugs Today (Barc); 2013 Jun; 49(6):353-61. PubMed ID: 23807939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy.
    Codecasa LR; Toumi M; D'Ausilio A; Aiello A; Damele F; Termini R; Uglietti A; Hettle R; Graziano G; De Lorenzo S
    J Mark Access Health Policy; 2017; 5(1):1283105. PubMed ID: 28265350
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
    Schnippel K; Ndjeka N; Maartens G; Meintjes G; Master I; Ismail N; Hughes J; Ferreira H; Padanilam X; Romero R; Te Riele J; Conradie F
    Lancet Respir Med; 2018 Sep; 6(9):699-706. PubMed ID: 30001994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.